Skip to the reading
KLOW Arrangement

The sources behind this KLOW peptide reading

Here are the studies and public guidance used in these pages, with a few words on what each can answer.

GHK-Cu and collagen in cells

GHK-Cu and collagen in cells. Maquart and colleagues, 1988. GHK-Cu increased collagen production in skin cells grown in a dish. People weren’t treated.

GHK skin research reviewed

GHK skin research reviewed. Pickart and colleagues, 2015. A review of laboratory work and reports about creams. Those findings don’t establish injection safety.

KPV in cells and mice

KPV in cells and mice. Dalmasso and colleagues, 2008. KPV reduced inflammatory signals in cells and eased bowel inflammation caused in mice for the experiment. No human treatment group.

BPC-157 and rat Achilles tendons

BPC-157 and rat Achilles tendons. Staresinic and colleagues, 2003. BPC-157 improved healing of cut rat Achilles tendons. The experiment didn’t test KLOW or human tendon pain.

The BPC-157 infusion pilot

The BPC-157 infusion pilot. Lee and Burgess, 2025. Two adults received intravenous BPC-157. Both had received BPC-157 infusions before. This short report had no comparison group and didn’t test KLOW.

Full thymosin beta-4 in rats

Full thymosin beta-4 in rats. Malinda and colleagues, 1999. Wound-healing findings in rats concern the full protein. TB-500 is a different substance, a capped fragment.

Full thymosin beta-4 in people

Full thymosin beta-4 in people. Ruff and colleagues, 2010. Healthy volunteers received the full protein intravenously, with a placebo comparison. The study didn’t test TB-500 or KLOW.

FDA’s 2026 BPC-157 assessment

FDA’s 2026 BPC-157 assessment. FDA discusses small human studies and limited safety monitoring. Staff proposed against adding BPC-157 to the 503A list of compounding ingredients.

FDA’s 2026 KPV assessment

FDA’s 2026 KPV assessment. FDA reported finding no clinical studies or human exposure data, and gaps in animal safety testing. Staff proposed against 503A list placement.

FDA’s 2026 TB-500 assessment

FDA’s 2026 TB-500 assessment. FDA distinguishes the fragment from the full protein and reported finding no published human TB-500 studies. Staff proposed against 503A list placement.

FDA’s safety and withdrawal record

FDA’s safety and withdrawal record. Marked current April 22, 2026. BPC-157, KPV, TB-500 and injectable GHK-Cu have withdrawn nominations and listed safety concerns. No individual withdrawal dates.

FDA’s non-injectable GHK-Cu entry

FDA’s non-injectable GHK-Cu entry. Updated May 14, 2026. Non-injectable GHK-Cu is in Category 1: enforcement discretion under conditions while FDA evaluates it. This isn’t approval.

FDA’s explanation of compounding

FDA’s explanation of compounding. Compounded medicines are not FDA-approved. Preparing a medicine for a patient is different from FDA review of its safety, effectiveness and quality.

FDA on compounding risks

FDA on compounding risks. FDA explains the lack of review before marketing and risks of poor quality. This is general information, not a KLOW product evaluation.

The 2026 world anti-doping list

The 2026 world anti-doping list. The World Anti-Doping Agency names thymosin beta-4 and derivatives including TB-500 as prohibited at all times, both in and out of competition.

HHS on telehealth licensing

HHS on telehealth licensing. The patient’s location matters for a clinician’s licence. This guidance explains why an online appointment still involves state rules, without guaranteeing access.

These are ingredient studies and public guidance. None tests the four-part KLOW blend in a controlled study. Return to the four voices for the introductions.